{"entity":{"id":"nct07533123","kind":"trial","name":"A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care","aka":[],"tldr":"A phase 3 trial testing JSKN016 in triple-negative breast cancer, now recruiting.","summary":"A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care. ClinicalTrials.gov record last updated 2026-04-16: recruiting. Enrollment is planned at 364 participants. Primary completion is estimated at 2029-03-17. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: JSKN016 Injection, Eribulin Mcsilate Injection, Vinorelbine Tartrate Injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Sacituzumab Govitecan for Injection. Registered primary measures: PFS (Progression-Free Survival); OS (Overall Survival).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07533123","url":"https://clinicaltrials.gov/study/NCT07533123"}],"tags":["ctgov-ingest"],"related":[],"cancers":["tnbc","tnbc-metastatic"],"sections":[],"technologies":[],"targets":["trop2"],"drugs":["jskn016"],"companies":["alphamab"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-04-16: recruiting. Enrollment is planned at 364 participants. Primary completion is estimated at 2029-03-17. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT07533123","phase":"3","setting":"A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care","sponsor":"Jiangsu Alphamab Biopharmaceuticals","participation":[{"nct":"NCT07533123","source":"https://clinicaltrials.gov/study/NCT07533123","fetchedAt":"2026-10-07T16:55:48.292Z","studySha256":"937932097d986ffb67645a5a33f27ec8ae45f5f7de9ce5dca7363f52c036dac7","overallStatus":"RECRUITING","lastUpdatePosted":"2026-04-16","leadSponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":364,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-03-17","startedType":"estimated","enrolled":364,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07533123/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"jskn016","kind":"drug","name":"JSKN016","route":"/drugs/jskn016/"}],"company":[{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/"}]}}